Cardiovascular Drugs Market Global Report 2017
出 版 商：TBRC
出版日期：2017/07/17
頁 數：125頁
文件格式：PDF
價 格：
USD 4,000 (Single-User License)
USD 6,000 (Multi-User License)
USD 8,000 (Global-User License)
USD 4,000 (Hard copy)
USD 6,000 (Multi-User License)
USD 8,000 (Global-User License)
USD 4,000 (Hard copy)
Innovation of gene testing technologies for the development of personalized medicine for cardiovascular diseases is one of the major trend in the market. Due to the reduction in the cost of gene testing, patients can screen for their predisposition for specific cardiovascular diseases. Gene testing helps in development of personalized pharmacogenomic agents and improved patient monitoring efforts and detect them before an onset of acute care episodes.
The Cardiovascular Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global cardiovascular drugs sector.
Reasons to Purchase
‧ Outperform competitors using accurate up to date demand-side dynamics information.
‧ Identify growth segments for investment.
‧ Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
‧ Create regional and country strategies on the basis of local data and analysis.
‧ Stay abreast of the latest customer and market research findings
‧ Benchmark performance against key competitors.
‧ Develop strategies based on likely future developments.
‧ Utilize the relationships between key data sets for superior strategizing.
‧ Suitable for supporting your internal and external presentations with reliable high quality data and analysis
‧ Gain a global perspective on the development of the market.
‧ Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the cardiovascular drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiovascular drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.
‧ The market characteristics section of the report defines and explains the market.
‧ The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
‧ Market segmentations break down market into sub markets.
‧ The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
‧ Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
‧ The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
‧ The Cardiovascular Drugs market section of the report gives context. It compares the cardiovascular drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Cardiovascular Drugs Indicators Comparison.
‧ The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.
Scope
Markets Covered: Anti-Hypertensive, Hypolipidemics, Anti Thrombotics, Others (Congestive Heart Failure, Anti- Arrythmic And Anti-Anginal Drugs)
Companies Mentioned: Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, and Novartis AG
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Cardiovascular Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
The Cardiovascular Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global cardiovascular drugs sector.
Reasons to Purchase
‧ Outperform competitors using accurate up to date demand-side dynamics information.
‧ Identify growth segments for investment.
‧ Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
‧ Create regional and country strategies on the basis of local data and analysis.
‧ Stay abreast of the latest customer and market research findings
‧ Benchmark performance against key competitors.
‧ Develop strategies based on likely future developments.
‧ Utilize the relationships between key data sets for superior strategizing.
‧ Suitable for supporting your internal and external presentations with reliable high quality data and analysis
‧ Gain a global perspective on the development of the market.
‧ Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the cardiovascular drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiovascular drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.
‧ The market characteristics section of the report defines and explains the market.
‧ The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
‧ Market segmentations break down market into sub markets.
‧ The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
‧ Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
‧ The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
‧ The Cardiovascular Drugs market section of the report gives context. It compares the cardiovascular drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Cardiovascular Drugs Indicators Comparison.
‧ The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.
Scope
Markets Covered: Anti-Hypertensive, Hypolipidemics, Anti Thrombotics, Others (Congestive Heart Failure, Anti- Arrythmic And Anti-Anginal Drugs)
Companies Mentioned: Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, and Novartis AG
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Cardiovascular Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
1. Cardiovascular Drugs Market Characteristics;
2. Cardiovascular Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Cardiovascular Drugs Market Customer Information;
5. Cardiovascular Drugs Market Segmentation;
5.1. Global Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 5.2. Global Cardiovascular Drugs Market, 2012 - 2020, Historic And Forecast, By Segment; 5.3 Global Cardiovascular Drugs Market Trends And Strategies;
6. Cardiovascular Drugs Market Regional And Country Analysis;
6.1. Global Cardiovascular Drugs Market, 2016, By Region; 6.2. Global Cardiovascular Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 6.3. Cardiovascular Drugs Market, 2016, By Country; 6.4. Cardiovascular Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country
7. Global Cardiovascular Drugs Market Comparison With Macro Economic Factors;
7.1. Cardiovascular Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Cardiovascular Drugs Expenditure, Global;
8. Cardiovascular Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Cardiovascular Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Cardiovascular Drugs Expenditure, By Country;
9. Cardiovascular Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Cardiovascular Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Cardiovascular Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Cardiovascular Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Cardiovascular Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Hypertension, 2014, By Country; 9.10. Prevalent Cases Of Parkinsons Disease, 2014, By Country; 9.11. Global Number Of General Practitioners 2016, By Country; 9.12. Global Cardiovascular Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;
10. Asia-Pacific Cardiovascular Drugs Market;
10.1.1. Asia-Pacific Cardiovascular Drugs Market Overview; 10.1.2. Asia-Pacific Cardiovascular Drugs Historic Market, 2012 - 2016; 10.1.3. Asia-Pacific Cardiovascular Drugs Forecast Market, 2016 - 2020; 10.1.4. Asia-Pacific Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.2. Asia-Pacific Cardiovascular Drugs Market: Country Analysis; 10.3. China Cardiovascular Drugs Market; 10.3.1. China Cardiovascular Drugs Market Overview; 10.3.2. China Cardiovascular Drugs Historic Market, 2012 - 2016; 10.3.3. China Cardiovascular Drugs Forecast Market, 2016 - 2020; 10.3.4. China Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.3.5. China Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 10.3.6. China Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 10.4. India Cardiovascular Drugs Market; 10.4.1. India Cardiovascular Drugs Market Overview; 10.4.2. India Cardiovascular Drugs Historic Market, 2012 - 2016; 10.4.3. India Cardiovascular Drugs Forecast Market, 2016 - 2020; 10.4.4. India Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.4.5. India Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 10.4.6. India Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 10.5. Japan Cardiovascular Drugs Market; 10.5.1. Japan Cardiovascular Drugs Market Overview; 10.5.2. Japan Cardiovascular Drugs Historic Market, 2012 - 2016; 10.5.3. Japan Cardiovascular Drugs Forecast Market, 2016 - 2020; 10.5.4. Japan Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.5.5. Japan Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 10.5.6. Japan Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 10.6. Australia Cardiovascular Drugs Market; 10.6.1. Australia Cardiovascular Drugs Historic Market, 2012 - 2016; 10.6.2. Australia Cardiovascular Drugs Forecast Market, 2016 - 2020; 10.6.3. Australia Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.6.4. Australia Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 10.6.5. Australia Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020;
11. Western Europe Cardiovascular Drugs Market;
11.1.1. Western Europe Cardiovascular Drugs Market Overview; 11.1.2. Western Europe Cardiovascular Drugs Historic Market, 2012 - 2016; 11.1.3. Western Europe Cardiovascular Drugs Forecast Market, 2016 - 2020; 11.1.4. Western Europe Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.2. Western Europe Cardiovascular Drugs Market: Country Analysis; 11.3. UK Cardiovascular Drugs Market; 11.3.1. UK Cardiovascular Drugs Market Overview; 11.3.2. UK Cardiovascular Drugs Historic Market, 2012 - 2016; 11.3.3. UK Cardiovascular Drugs Forecast Market, 2016 - 2020; 11.3.4. UK Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.3.5. UK Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 11.3.6. UK Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 11.4. Germany Cardiovascular Drugs Market; 11.4.1. Germany Cardiovascular Drugs Historic Market, 2012 - 2016; 11.4.2. Germany Cardiovascular Drugs Forecast Market, 2016 - 2020; 11.4.3. Germany Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.4.4 Germany Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 11.4.5 Germany Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 11.5 France Cardiovascular Drugs Market; 11.5.1 France Cardiovascular Drugs Historic Market, 2012 - 2016; 11.5.2 France Cardiovascular Drugs Forecast Market, 2016 - 2020; 11.5.3 France Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.5.4 France Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 11.5.5 France Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 11.6. Italy Cardiovascular Drugs Market; 11.6.1. Italy Cardiovascular Drugs Historic Market, 2012 - 2016; 11.6.2. Italy Cardiovascular Drugs Forecast Market, 2016 - 2020; 11.6.3. Italy Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.6.4. Italy Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 11.6.5. Italy Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 11.7. Spain Cardiovascular Drugs Market; 11.7.1. Spain Cardiovascular Drugs Historic Market, 2012 - 2016; 11.7.2. Spain Cardiovascular Drugs Forecast Market, 2016 - 2020; 11.7.3. Spain Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.7.4. Spain Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 11.7.5. Spain Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020;
12. Eastern Europe Cardiovascular Drugs Market;
12.1.1. Eastern Europe Cardiovascular Drugs Market Overview; 12.1.2. Eastern Europe Cardiovascular Drugs Historic Market, 2012 - 2016; 12.1.3. Eastern Europe Cardiovascular Drugs Forecast Market, 2016 - 2020; 12.1.4 Eastern Europe Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 12.2. Eastern Europe Cardiovascular Drugs Market: Country Analysis; 12.3. Russia Cardiovascular Drugs Market; 12.3.1. Russia Cardiovascular Drugs Historic Market, 2012 - 2016; 12.3.2. Russia Cardiovascular Drugs Forecast Market, 2016 - 2020; 12.3.3. Russia Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 12.3.4. Russia Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 12.3.5. Russia Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020;
13. North America Cardiovascular Drugs Market;
13.1.1. North America Cardiovascular Drugs Market Overview; 13.1.2. North America Cardiovascular Drugs Historic Market, 2012 - 2016; 13.1.3. North America Cardiovascular Drugs Forecast Market, 2016 - 2020; 13.1.4. North America Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 13.2. North America Cardiovascular Drugs Market: Country Analysis; 13.3. USA Cardiovascular Drugs Market; 13.3.1. USA Cardiovascular Drugs Historic Market, 2012 - 2016; 13.3.2. USA Cardiovascular Drugs Forecast Market, 2016 - 2020; 13.3.3 USA Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 13.3.4. USA Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 13.3.5. USA Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020;
14. South America Cardiovascular Drugs Market;
14.1.1. South America Cardiovascular Drugs Market Overview; 14.1.2. South America Cardiovascular Drugs Historic Market, 2012 - 2016; 14.1.3. South America Cardiovascular Drugs Forecast Market, 2016 - 2020; 14.1.4. South America Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 14.2. South America Cardiovascular Drugs Market: Country Analysis; 14.3. Brazil Cardiovascular Drugs Market; 14.3.1. Brazil Cardiovascular Drugs Historic Market, 2012 - 2016; 14.3.2. Brazil Cardiovascular Drugs Forecast Market, 2016 - 2020; 14.3.3. Brazil Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 14.3.4. Brazil Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 14.3.5. Brazil Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020;
15. Middle East Cardiovascular Drugs Market;
15.1.1. Middle East Cardiovascular Drugs Market Overview; 15.1.2. Middle East Cardiovascular Drugs Historic Market, 2012 - 2016; 15.1.3. Middle East Cardiovascular Drugs Forecast Market, 2016 - 2020; 15.1.4. Middle East Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs);
16. Africa Cardiovascular Drugs Market;
16.1.1. Africa Cardiovascular Drugs Market Overview; 16.1.1. Africa Cardiovascular Drugs Market Overview; 16.1.2. Africa Cardiovascular Drugs Historic Market, 2012 - 2016; 16.1.3. Africa Cardiovascular Drugs Forecast Market, 2016 - 2020; 16.1.4. Africa Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs);
17. Cardiovascular Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. Bristol-Myers Squibb Company; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Abbott Laboratories Inc.; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Astrazeneca Plc; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Bayer Ag; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Novartis Ag; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Cardiovascular Drugs Market;
19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 19.2.5 Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
2. Cardiovascular Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Cardiovascular Drugs Market Customer Information;
5. Cardiovascular Drugs Market Segmentation;
5.1. Global Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 5.2. Global Cardiovascular Drugs Market, 2012 - 2020, Historic And Forecast, By Segment; 5.3 Global Cardiovascular Drugs Market Trends And Strategies;
6. Cardiovascular Drugs Market Regional And Country Analysis;
6.1. Global Cardiovascular Drugs Market, 2016, By Region; 6.2. Global Cardiovascular Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 6.3. Cardiovascular Drugs Market, 2016, By Country; 6.4. Cardiovascular Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country
7. Global Cardiovascular Drugs Market Comparison With Macro Economic Factors;
7.1. Cardiovascular Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Cardiovascular Drugs Expenditure, Global;
8. Cardiovascular Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Cardiovascular Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Cardiovascular Drugs Expenditure, By Country;
9. Cardiovascular Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Cardiovascular Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Cardiovascular Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Cardiovascular Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Cardiovascular Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Hypertension, 2014, By Country; 9.10. Prevalent Cases Of Parkinsons Disease, 2014, By Country; 9.11. Global Number Of General Practitioners 2016, By Country; 9.12. Global Cardiovascular Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;
10. Asia-Pacific Cardiovascular Drugs Market;
10.1.1. Asia-Pacific Cardiovascular Drugs Market Overview; 10.1.2. Asia-Pacific Cardiovascular Drugs Historic Market, 2012 - 2016; 10.1.3. Asia-Pacific Cardiovascular Drugs Forecast Market, 2016 - 2020; 10.1.4. Asia-Pacific Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.2. Asia-Pacific Cardiovascular Drugs Market: Country Analysis; 10.3. China Cardiovascular Drugs Market; 10.3.1. China Cardiovascular Drugs Market Overview; 10.3.2. China Cardiovascular Drugs Historic Market, 2012 - 2016; 10.3.3. China Cardiovascular Drugs Forecast Market, 2016 - 2020; 10.3.4. China Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.3.5. China Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 10.3.6. China Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 10.4. India Cardiovascular Drugs Market; 10.4.1. India Cardiovascular Drugs Market Overview; 10.4.2. India Cardiovascular Drugs Historic Market, 2012 - 2016; 10.4.3. India Cardiovascular Drugs Forecast Market, 2016 - 2020; 10.4.4. India Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.4.5. India Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 10.4.6. India Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 10.5. Japan Cardiovascular Drugs Market; 10.5.1. Japan Cardiovascular Drugs Market Overview; 10.5.2. Japan Cardiovascular Drugs Historic Market, 2012 - 2016; 10.5.3. Japan Cardiovascular Drugs Forecast Market, 2016 - 2020; 10.5.4. Japan Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.5.5. Japan Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 10.5.6. Japan Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 10.6. Australia Cardiovascular Drugs Market; 10.6.1. Australia Cardiovascular Drugs Historic Market, 2012 - 2016; 10.6.2. Australia Cardiovascular Drugs Forecast Market, 2016 - 2020; 10.6.3. Australia Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.6.4. Australia Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 10.6.5. Australia Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020;
11. Western Europe Cardiovascular Drugs Market;
11.1.1. Western Europe Cardiovascular Drugs Market Overview; 11.1.2. Western Europe Cardiovascular Drugs Historic Market, 2012 - 2016; 11.1.3. Western Europe Cardiovascular Drugs Forecast Market, 2016 - 2020; 11.1.4. Western Europe Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.2. Western Europe Cardiovascular Drugs Market: Country Analysis; 11.3. UK Cardiovascular Drugs Market; 11.3.1. UK Cardiovascular Drugs Market Overview; 11.3.2. UK Cardiovascular Drugs Historic Market, 2012 - 2016; 11.3.3. UK Cardiovascular Drugs Forecast Market, 2016 - 2020; 11.3.4. UK Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.3.5. UK Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 11.3.6. UK Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 11.4. Germany Cardiovascular Drugs Market; 11.4.1. Germany Cardiovascular Drugs Historic Market, 2012 - 2016; 11.4.2. Germany Cardiovascular Drugs Forecast Market, 2016 - 2020; 11.4.3. Germany Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.4.4 Germany Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 11.4.5 Germany Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 11.5 France Cardiovascular Drugs Market; 11.5.1 France Cardiovascular Drugs Historic Market, 2012 - 2016; 11.5.2 France Cardiovascular Drugs Forecast Market, 2016 - 2020; 11.5.3 France Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.5.4 France Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 11.5.5 France Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 11.6. Italy Cardiovascular Drugs Market; 11.6.1. Italy Cardiovascular Drugs Historic Market, 2012 - 2016; 11.6.2. Italy Cardiovascular Drugs Forecast Market, 2016 - 2020; 11.6.3. Italy Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.6.4. Italy Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 11.6.5. Italy Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020; 11.7. Spain Cardiovascular Drugs Market; 11.7.1. Spain Cardiovascular Drugs Historic Market, 2012 - 2016; 11.7.2. Spain Cardiovascular Drugs Forecast Market, 2016 - 2020; 11.7.3. Spain Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.7.4. Spain Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 11.7.5. Spain Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020;
12. Eastern Europe Cardiovascular Drugs Market;
12.1.1. Eastern Europe Cardiovascular Drugs Market Overview; 12.1.2. Eastern Europe Cardiovascular Drugs Historic Market, 2012 - 2016; 12.1.3. Eastern Europe Cardiovascular Drugs Forecast Market, 2016 - 2020; 12.1.4 Eastern Europe Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 12.2. Eastern Europe Cardiovascular Drugs Market: Country Analysis; 12.3. Russia Cardiovascular Drugs Market; 12.3.1. Russia Cardiovascular Drugs Historic Market, 2012 - 2016; 12.3.2. Russia Cardiovascular Drugs Forecast Market, 2016 - 2020; 12.3.3. Russia Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 12.3.4. Russia Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 12.3.5. Russia Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020;
13. North America Cardiovascular Drugs Market;
13.1.1. North America Cardiovascular Drugs Market Overview; 13.1.2. North America Cardiovascular Drugs Historic Market, 2012 - 2016; 13.1.3. North America Cardiovascular Drugs Forecast Market, 2016 - 2020; 13.1.4. North America Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 13.2. North America Cardiovascular Drugs Market: Country Analysis; 13.3. USA Cardiovascular Drugs Market; 13.3.1. USA Cardiovascular Drugs Historic Market, 2012 - 2016; 13.3.2. USA Cardiovascular Drugs Forecast Market, 2016 - 2020; 13.3.3 USA Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 13.3.4. USA Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 13.3.5. USA Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020;
14. South America Cardiovascular Drugs Market;
14.1.1. South America Cardiovascular Drugs Market Overview; 14.1.2. South America Cardiovascular Drugs Historic Market, 2012 - 2016; 14.1.3. South America Cardiovascular Drugs Forecast Market, 2016 - 2020; 14.1.4. South America Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 14.2. South America Cardiovascular Drugs Market: Country Analysis; 14.3. Brazil Cardiovascular Drugs Market; 14.3.1. Brazil Cardiovascular Drugs Historic Market, 2012 - 2016; 14.3.2. Brazil Cardiovascular Drugs Forecast Market, 2016 - 2020; 14.3.3. Brazil Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 14.3.4. Brazil Cardiovascular Drugs Percentage Of GDP, 2012 - 2020; 14.3.5. Brazil Per Capita Average Cardiovascular Drugs Expenditure, 2012 - 2020;
15. Middle East Cardiovascular Drugs Market;
15.1.1. Middle East Cardiovascular Drugs Market Overview; 15.1.2. Middle East Cardiovascular Drugs Historic Market, 2012 - 2016; 15.1.3. Middle East Cardiovascular Drugs Forecast Market, 2016 - 2020; 15.1.4. Middle East Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs);
16. Africa Cardiovascular Drugs Market;
16.1.1. Africa Cardiovascular Drugs Market Overview; 16.1.1. Africa Cardiovascular Drugs Market Overview; 16.1.2. Africa Cardiovascular Drugs Historic Market, 2012 - 2016; 16.1.3. Africa Cardiovascular Drugs Forecast Market, 2016 - 2020; 16.1.4. Africa Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs);
17. Cardiovascular Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. Bristol-Myers Squibb Company; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Abbott Laboratories Inc.; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Astrazeneca Plc; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Bayer Ag; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Novartis Ag; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Cardiovascular Drugs Market;
19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 19.2.5 Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment
19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
